U.S. NUCLEAR REGULATORY COMMISSION Amendment No. 77

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated July 27, 2009
1. St. Vincent Healthcare	3. License number 25-07553-01 is amended in its entirety to read as follows:
2. P.O. Box 35200 Billings, Montana 59107-5200	4. Expiration date April 30, 2015
	5. Docket No. 030-02396 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (3M Model Nos. 6500, 6501, 6502, 6503 and 6504; Bard Brachytherapy Model STM-1251; Theragenics Model 200; Best Medical International Model 81-01 Series and Model 2301; Amersham Health, Medi-Physics, Inc., Model 6711 Oncoseed™)	D. 1500 millicuries
E. Any byproduct materials identified in 10 CFR 31.11	E. Prepackage Kits	E. 10 millicuries
F. Iodine-125 permitted by 10 CFR 35.1000	F. Liquid brachytherapy source Proxima Therapeutics, Inc. Iotrex™	F. 5 curies
G. Strontium-90 permitted by 10 CFR 35.1000	G. Sealed sources (Amersham Corporation Model SIA.20)	G. 90 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
25-07553-01

Docket or Reference Number
030-02396

Amendment No. 77

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any use permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. In vitro studies.
F. For brachytherapy use in Proxima Therapeutics' GliaSite® Radiation Therapy System permitted by 10 CFR 35.1000.
G. For ophthalmic radiation therapy permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at:

A. 1233 North 30th Street, Billings, Montana, for material listed in Items 6.A. through 6.G
B. 2900 12th Avenue North, Billings, Montana, for material listed in Items 6.A. and 6.B.
C. Yellowstone Surgery Center, 1144 North 28th Street, Billings, Montana, for material listed in Items 6.B. and 6.D.
D. Licensed material may be used only at the licensee's facility located at Yellowstone Imaging Center, 2900 12th Avenue North, Suite 275W, Billings, Montana, for material listed in Item 6.B.

11. The Radiation Safety Officer for this license is Rodney J. Wimmer, Ph.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for the material and medical uses indicated:

Authorized Users	Material and Use
Joseph C. Apostol, M.D.	35.200
Michael W. Brennan, M.D.	35.200
Paul LaVeau, M.D.	35.200
James K. Vincent, M.D.	35.200
Mitchell E. Gallagher, M.D.	35.100; 35.200; 31.11
Joseph P. Dillard, M.D.	35.100; 35.200; 31.11
Ann Giuliano, M.D.	35.100; 35.200; 35.300; 31.11
Robert Rex Dietz, M.D.	35.100; 35.200; 35.300
Kathleen A. Ryan, M.D.	35.100; 35.200; 35.300
John M. Schallenkamp, M.D.	35.400
John V. Hanson, M.D.	35.100; 35.200; 31.11; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
25-07553-01

Docket or Reference Number
030-02396

Amendment No. 77

Authorized Users	Material and Use
John S. Brandon, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
John Gerard Terry, M.D.	35.300; 35.400; Sr-90 for ophthalmic radiation therapy; 35.1000 only for Iodine-125 Iotrex™ in Proxima Therapeutics' GliaSite® Radiation Therapy System
Robert L. Stears, M.D.	35.100; 35.200

C. The following individuals are authorized users for non-medical uses indicated:

Authorized Users	Material and Use
Hoyle Setzer, M.D.	31.11

D. The following individual is an authorized medical physicist:

Authorized Medical Physicist	Material and Use
Rodney J. Wimmer, Ph.D.	Sr-90 in an ophthalmic applicator for activity calculation
David W. Switzer, M.S.	Sr-90 in an ophthalmic applicator for activity calculation

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
25-07553-01

Docket or Reference Number
030-02396

Amendment No. 77

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 21, 2004 (ML063180067)
B. Letter dated November 23, 2004 (ML043280649)
C. Letter dated April 18, 2005 (ML051150232)
D. Facsimile dated April 22, 2005 (ML051150214)
E. Facsimile dated October 17, 2005 (ML062920135)
F. Letter dated November 27, 2006 (ML063380384)
G. E-Mail dated December 4, 2006 (ML063380368 and ML063380384)
H. Letter dated July 27, 2009 (ML092380334)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: November 6, 2009

By: _____
Jacqueline D. Cook, Senior Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011-4125